Evidence map›Paper›PMID 26733802›Full record

ArticleFrontiers in molecular neuroscience2015

Disturbances of Ligand Potency and Enhanced Degradation of the Human Glycine Receptor at Affected Positions G160 and T162 Originally Identified in Patients Suffering from Hyperekplexia.

Sinem Atak, Georg Langlhofer, Natascha Schaefer, Denise Kessler, Heike Meiselbach, Carolyn Delto, Hermann Schindelin, Carmen Villmann

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Molecular Pharmacology ofInternational journal of molecular sciences · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. A Novel Glycine Receptor Variant with Startle Disease Affects Syndapin I and Glycinergic Inhibition.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
    Article
  6. Impaired Glycine Receptor Trafficking in Neurological Diseases.Frontiers in molecular neuroscience · 2018
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sinem AtakInstitute for Clinical Neurobiology, Julius-Maximilians-University of Würzburg Würzburg, Germany.
Georg LanglhoferInstitute for Clinical Neurobiology, Julius-Maximilians-University of Würzburg Würzburg, Germany.
Natascha SchaeferInstitute for Clinical Neurobiology, Julius-Maximilians-University of Würzburg Würzburg, Germany.
Denise KesslerInstitute for Clinical Neurobiology, Julius-Maximilians-University of Würzburg Würzburg, Germany.
Heike MeiselbachBioinformatics Department, Institute of Biochemistry, Friedrich-Alexander-University Erlangen-Nürnberg Erlangen, Germany.
Carolyn DeltoRudolf Virchow Center for Experimental Biomedicine Würzburg, Germany.
Hermann SchindelinRudolf Virchow Center for Experimental Biomedicine Würzburg, Germany.
Carmen VillmannInstitute for Clinical Neurobiology, Julius-Maximilians-University of Würzburg Würzburg, Germany.
University of Würzburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ligand-binding of Cys-loop receptors is determined by N-terminal extracellular loop structures from the plus as well as from the minus side of two adjacent subunits in the pentameric receptor complex. An aromatic residue in loop B of the glycine receptor (GlyR) undergoes direct interaction with the incoming ligand via a cation-π interaction. Recently, we showed that mutated residues in loop B identified from human patients suffering from hyperekplexia disturb ligand-binding. Here, we exchanged the affected human residues by amino acids found in related members of the Cys-loop receptor family to determine the effects of side chain volume for ion channel properties. GlyR variants were characterized in vitro following transfection into cell lines in order to analyze protein expression, trafficking, degradation and ion channel function. GlyR α1 G160 mutations significantly decrease glycine potency arguing for a positional effect on neighboring aromatic residues and consequently glycine-binding within the ligand-binding pocket. Disturbed glycinergic inhibition due to T162 α1 mutations is an additive effect of affected biogenesis and structural changes within the ligand-binding site. Protein trafficking from the ER toward the ER-Golgi intermediate compartment, the secretory Golgi pathways and finally the cell surface is largely diminished, but still sufficient to deliver ion channels that are functional at least at high glycine concentrations. The majority of T162 mutant protein accumulates in the ER and is delivered to ER-associated proteasomal degradation. Hence, G160 is an important determinant during glycine binding. In contrast, T162 affects primarily receptor biogenesis whereas exchanges in functionality are secondary effects thereof.

Indexed as

Cys-loop receptorglycine receptorhyperekplexialigand potenciesloop Bside chain properties

Identifiers

PMID26733802
PMCPMC4686643
OpenAlexW2206889870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.